CEACAM5 and breast carcinoma: Nevertheless, the American Society of Clinical Oncology (ASCO) guidelines do not recommend use of CEA and CA15.3 alone for monitoring the response of breast cancer to treatment; they do, however, consider that these biomarkers may be used as adjunct assessments in the choice of therapy for metastatic breast cancer [16].